Celecoxib decreases the viability of MDA-MB-231-and MDA-MB-435-stable transfectants

<p><b>Copyright information:</b></p><p>Taken from "Adenovirus type 5 -induced apoptosis in COX-2-overexpressing breast cancer cells"</p><p>Breast cancer research : BCR 2007;9(4):R41-R41.</p><p>Published online 5 Jul 2007</p><p>PMCID:PMC2206712.</p><p></p> MTT assays after a 5-day exposure to 0–60 μM celecoxib indicate substantial reductions in cell viability in all variants of the MDA-MB-231 and MDA-MB-435 cell lines (stable transfectants, vector control, and parental control cells). Each point represents means from tests performed in quadruplicate; the bars are standard deviations. In both cell lines, the transfectants were more sensitive than the vector control or parental control cells. MTT assays in all variants of the SKOV3.ip1 and MCF-7 cell lines. The transfectants have no difference to sensitivity for celecoxib in both cell lines. Trypan blue assays after a 5-day exposure to 40 μM celecoxib show substantial reductions in viability of MDA-MB-231 and MDA-MB-435 cells. Values shown are normalized to the viability of the control (untreated) cells. Each bar represents means from tests performed in quadruplicate; bars are standard deviations. values are from two-tailed paired tests